NZ515356A - Crystallised Fab'-epitope complex from the HIV-1 cross- neutralizing monoclonal antibody 2F5 - Google Patents

Crystallised Fab'-epitope complex from the HIV-1 cross- neutralizing monoclonal antibody 2F5

Info

Publication number
NZ515356A
NZ515356A NZ515356A NZ51535600A NZ515356A NZ 515356 A NZ515356 A NZ 515356A NZ 515356 A NZ515356 A NZ 515356A NZ 51535600 A NZ51535600 A NZ 51535600A NZ 515356 A NZ515356 A NZ 515356A
Authority
NZ
New Zealand
Prior art keywords
fab
hiv
crystallised
cross
monoclonal antibody
Prior art date
Application number
NZ515356A
Other languages
English (en)
Inventor
Emil F Pai
Michel H Klein
Pele Chong
Arthur Pedyczak
Original Assignee
Univ Toronto
Aventis Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Toronto, Aventis Pasteur filed Critical Univ Toronto
Publication of NZ515356A publication Critical patent/NZ515356A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NZ515356A 1999-04-13 2000-04-05 Crystallised Fab'-epitope complex from the HIV-1 cross- neutralizing monoclonal antibody 2F5 NZ515356A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/289,942 US6482928B1 (en) 1999-04-13 1999-04-13 Fab′-epitope complex from HIV-1 cross-neutralizing monoclonal antibody 2F5
PCT/CA2000/000358 WO2000061618A1 (en) 1999-04-13 2000-04-05 Fab-EPITOPE COMPLEX FROM THE HIV-1 CROSS-NEUTRALIZING MONOCLONAL ANTIBODY 2F5

Publications (1)

Publication Number Publication Date
NZ515356A true NZ515356A (en) 2004-02-27

Family

ID=23113847

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ515356A NZ515356A (en) 1999-04-13 2000-04-05 Crystallised Fab'-epitope complex from the HIV-1 cross- neutralizing monoclonal antibody 2F5

Country Status (8)

Country Link
US (2) US6482928B1 (xx)
EP (1) EP1203017A1 (xx)
JP (2) JP4011856B2 (xx)
AU (1) AU765680B2 (xx)
CA (1) CA2371929C (xx)
MX (1) MXPA01010437A (xx)
NZ (1) NZ515356A (xx)
WO (1) WO2000061618A1 (xx)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2724320B1 (fr) * 1994-09-13 1996-12-20 Transgene Sa Nouvel implant pour le traitement des maladies acquises
US7018637B2 (en) * 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
AU2002327171A1 (en) 2001-05-01 2003-01-02 Medimmune, Inc. Crystals and structure of synagis fab
CA2539437A1 (en) * 2003-09-19 2005-03-31 The Scripps Research Institute Peptide that binds to a broadly neutralizing anti-hiv antibody-structure of 4e10 fab fragment complex, uses thereof, compositions therefrom
US8147840B2 (en) 2004-05-14 2012-04-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human immunodeficiency virus (HIV) immunization strategies employing conformationally-stabilized, surface-occluded peptides comprising a gp41 2F5 epitope in association with lipid
RU2442571C2 (ru) * 2004-07-23 2012-02-20 Дженентек, Инк. Кристаллизация антител или их фрагментов
JP4892548B2 (ja) * 2005-05-02 2012-03-07 アンスティテュト ナショナル ド ラ サンテ エ ド ラ ルシェルシュ メディカル （アンセルム） Ｈｉｖに対して中和活性を有する抗体又はその断片
WO2008025015A2 (en) * 2006-08-25 2008-02-28 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Epitope-protein scaffolds and their use
EP2172481B1 (en) * 2008-10-06 2014-10-29 Novoplant GmbH Proteolytically stable antibody formats
WO2010040545A1 (en) * 2008-10-06 2010-04-15 Novoplant Gmbh Proteolytically stable antibody formats
WO2016037154A1 (en) 2014-09-04 2016-03-10 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Recombinant hiv-1 envelope proteins and their use
EP3786180A1 (en) * 2019-08-27 2021-03-03 Diaccurate Antibodies and the uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5831034A (en) 1987-11-13 1998-11-03 Hermann Katinger Human monoclonal anti-HIV-I-antibodies
US5652138A (en) 1992-09-30 1997-07-29 The Scripps Research Institute Human neutralizing monoclonal antibodies to human immunodeficiency virus
EP0725825B1 (en) 1993-09-11 2001-02-21 Polymun Scientific Immunbiologische Forschung GmbH Peptides that elicit neutralizing antibodies against genetically divergent hiv-1 strains

Also Published As

Publication number Publication date
CA2371929A1 (en) 2000-10-19
US7342090B1 (en) 2008-03-11
JP2002542166A (ja) 2002-12-10
WO2000061618A1 (en) 2000-10-19
US6482928B1 (en) 2002-11-19
AU3651000A (en) 2000-11-14
JP4011856B2 (ja) 2007-11-21
JP2006328047A (ja) 2006-12-07
AU765680B2 (en) 2003-09-25
EP1203017A1 (en) 2002-05-08
MXPA01010437A (es) 2003-07-21
CA2371929C (en) 2013-08-06

Similar Documents

Publication Publication Date Title
Gorny et al. Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120.
Earl et al. Epitope map of human immunodeficiency virus type 1 gp41 derived from 47 monoclonal antibodies produced by immunization with oligomeric envelope protein
Broliden et al. Identification of human neutralization-inducing regions of the human immunodeficiency virus type 1 envelope glycoproteins.
Gorny et al. Production of site-selected neutralizing human monoclonal antibodies against the third variable domain of the human immunodeficiency virus type 1 envelope glycoprotein.
Zwick et al. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41
RU96102594A (ru) Тандемные синтетические hiv-1 пептиды
Gorny et al. Recognition by human monoclonal antibodies of free and complexed peptides representing the prefusogenic and fusogenic forms of human immunodeficiency virus type 1 gp41
Pietzsch et al. Anti-gp41 antibodies cloned from HIV-infected patients with broadly neutralizing serologic activity
ID30497A (id) Peptida hiv, antigen, komposisi vaksin, kit imunoasai dan metoda untuk mendeteksi antibodi yang diinduksi oleh hiv
NZ515356A (en) Crystallised Fab'-epitope complex from the HIV-1 cross- neutralizing monoclonal antibody 2F5
MY136081A (en) Modified hiv - 1gag p17 peptide and immunogenic composition
US6245895B1 (en) Antigen/antibody specificity exchanger
EP0388602B1 (en) Monoclonal antibody for differentiating HIV-2 from HIV-1 seropositive individuals
WO2002081655A3 (en) Fusion protein construct and method for inducing hiv-specific serum igg and secretory iga antibodies in-vivo
US6008044A (en) Human monoclonal antibodies directed against the transmembrane glycoprotein (gp41) of human immunodeficiency virus-1 (HIV-1) and detection of antibodies against epitope (GCSGKLIC)
Cotropia et al. A human monoclonal antibody to HIV-1 gp41 with neutralizing activity against diverse laboratory isolates
EP0492560A3 (en) Human monoclonal antibodies directed against the transmembrane glycoprotein (gp41) of hiv-1, and related peptides
Stamatos et al. Neutralizing antibodies from the sera of human immunodeficiency virus type 1-infected individuals bind to monomeric gp120 and oligomeric gp140
WO2002020555A3 (en) Hiv peptides from tat, rev and wef conserved regions and their application as e.g.vaccine components
Xiao et al. Epitope-vaccine induces high levels of ELDKWA-epitope-specific neutralizing antibody
Avrameas et al. Localisation of three epitopes of the env protein of feline immunodeficiency virus
WO2003022879A3 (en) Peptides mimicking a cryptic epitope of gp41 hiv-1 and antibodies directed against them
Gorny et al. Human monoclonal antibodies that neutralize HIV-1
Hewer et al. Peptide immunogens based on the envelope region of HIV-1 are recognized by HIV/AIDS patient polyclonal antibodies and induce strong humoral immune responses in mice and rabbits
Reading et al. A novel monoclonal antibody specific to the C-terminal tail of the gp41 envelope transmembrane protein of human immunodeficiency virus type 1 that preferentially neutralizes virus after it has attached to the target cell and inhibits the production of infectious progeny

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 7 YEARS UNTIL 05 APR 2020 BY CPA GLOBAL

Effective date: 20130221

EXPY Patent expired